News | Stroke | August 24, 2022

iHealthScreen Inc. Introduces An Automated Stroke Prediction Model, based on AI and Color Fundus Imaging

iHealthScreen is the First Company to Develop An AI- and Color-Fundus- Image-Based Stroke Prediction model, Funded by the National Institutes of Health (NIH) 

iHealthScreen is the First Company to Develop An AI- and Color-Fundus- Image-Based Stroke Prediction model, Funded by the National Institutes of Health (NIH) 


August 24, 2022 — iPredict late stroke prediction model provides a fully automated prediction score for incident stroke and identifies the individuals who are at risk of stroke within 5-years. These results were presented at the international conference: Society for Brain Mapping and Therapeutics World Congress and show that the prediction model may help prevent stroke, saving millions of people from death or disability. 

Once high-resolution images of the patient’s eyes have been captured using a color fundus camera and submitted to the iPredict AI System, the stroke prediction results are available in a fully automated report in less than 60 seconds. The entire test can easily and reliably be completed within 5 minutes. 

This prediction model offers an overall accuracy of 82.4% for identifying an individual at risk of having an incident stroke within 5-years. 

iPredict achieved higher accuracy than existing stroke prediction models such as Framingham and Chads scores (iPredict-stroke accuracy 82.4% compared to Framingham score 64.9%, and the CHADS2VASC score achieved 63.8% accuracy respectively on the same dataset). 

iPredict’s stroke model can be used to alert physicians of the need to take further preventive measures for these patients in the primary care setting. 

The company also has AI-based screening tools for early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma which are CE certified and TGA/Australian health approved. 

For more information: https://www.iHealthScreen.org 


Related Content

News | Heart Failure

July 28, 2026 — Abbott has initiated the Treat TR study, a post-market study of the company’s TriClip transcatheter edge ...

Home July 29, 2026
Home
News | Heart Failure

July 22, 2026 — Ultromics has announced results from an independent clinical data set that shows the company’s EchoGo ...

Home July 22, 2026
Home
News | Heart Failure

June 29, 2026 — A new international expert consensus document refines and updates how heart failure is identified and ...

Home June 30, 2026
Home
News | Heart Failure

May 28, 2026 — Coredio has announced that the U.S. Food and Drug Administration (FDA) has granted its Cardiac ...

Home May 28, 2026
Home
News | Heart Failure

May 10, 2026 — WhiteSwell has announced primary results from the DELTA-HF feasibility clinical trial evaluating the eLym ...

Home May 21, 2026
Home
Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
Subscribe Now